Status:

COMPLETED

Rollover Study Protocol for Pediatric Patients in South Africa for Continued Access to Emtricitabine

Lead Sponsor:

Gilead Sciences

Conditions:

HIV-1 Infection

Eligibility:

All Genders

1-17 years

Phase:

PHASE2

Brief Summary

The primary objectives of this trial are to provide FTC-203 study participants in South Africa with continued access to the study drug, emtricitabine (FTC), following completion of the FTC-203 study a...

Eligibility Criteria

Inclusion

  • Key Inclusion Criteria:
  • Complete or have previously completed at least through the Week 96 Visit (i.e., 96 weeks on study) for the FTC-203 study.
  • Complete all End-of-Study Visit procedures for the FTC-203 study.
  • Either (a) have a plasma HIV-1 RNA viral load of ≤ 400 copies/mL at the End-of-Study Visit for the FTC-203 study, or (b) if the subject's plasma HIV-1 RNA viral load at the End-of-Study Visit for FTC-203 study is \> 400 copies/mL, their viral load is \< 1.0 log10 above the nadir recorded after Week 8 of the FTC-203 study and there is reliable genotypic evidence showing a lack of resistance to emtricitabine.
  • A parent or other legal guardian has provided written informed consent to the subject participating in the rollover protocol. As applicable, based on the subject's age and normal institution practice, the subject should additionally provide their written informed consent or assent to participate in the rollover protocol.
  • Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Exclusion

    Key Trial Info

    Start Date :

    November 22 2005

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    February 13 2017

    Estimated Enrollment :

    50 Patients enrolled

    Trial Details

    Trial ID

    NCT00743340

    Start Date

    November 22 2005

    End Date

    February 13 2017

    Last Update

    April 26 2018

    Active Locations (2)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (2 locations)

    1

    Themba Lethu Clinic, Helen Joseph Hospital, Westdene

    Johannesburg, South Africa

    2

    Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital

    Soweto, South Africa